옵션 체인은 다양한 행사가격과 만기일에 대한 Dr Reddy's Laboratories의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Dr Reddy's Laboratories에 대한 시장 심리를 평가합니다..

Dr Reddy's Laboratories (NYSE:RDY) 주식, 옵션 체인

Dr Reddy's Laboratories

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Large Cap

News

Movers

Trading Ideas

BIRK

CHWY

DOCS

KVYO

NBIX

TEVA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테바 파마수티컬스(NYSE:TEVA)의 주식은 회사와 사노피 SA(NASDAQ:SNY)가 궤양성 대장염 및 크론병에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories Ltd

Newpath Resources Inc

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) stock escalated 33.88% after the company and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced that primary endpoints were met in the Phase 2b trial of Duvakitug for <a href="https://www.benzinga.com//node/42531132" target="_blank" rel="noreferrer noopener">ulcerative colitis and Crohn&#8217;s disease</a>.</li>
<li>Klaviyo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) shares surged 12.85%.</li>
<li>Olive Garden parent Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) stock rose 12.54% after the company reported better-than-expected second-quarter EPS and <a href="https://www.benzinga.com//node/42585797" target="_blank" rel="noreferrer noopener">issued an FY25 revenue outlook</a>. Several analysts raised the <a href="https://www.benzinga.com/quote/dri/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares upped 10.91%. Stephens &amp; Co. initiated coverage with an Equal-Weight rating and <a href="https://www.benzinga.com/quote/docs/analyst-ratings" target="_blank" rel="noreferrer noopener">a price forecast of $55</a>.</li>
<li>Birkenstock Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) shares increased 9.70% after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance. Several analysts raised <a href="https://www.benzinga.com//node/42599431" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) stock upped 7.30% after the company reported better-than-expected <a href="https://www.benzinga.com//node/42553094" target="_blank" rel="noreferrer noopener">first-quarter EPS and revenues</a>. Several analysts raised <a href="https://www.benzinga.com/quote/jbl/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock rose 6.88%. The FDA approved Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with <a href="https://www.benzinga.com//node/42508449" target="_blank" rel="noreferrer noopener">classic congenital adrenal hyperplasia (CAH).</a></li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock was up 6.54% last week, continuing strength from Q3 earnings.</li>
<li>Dr. Reddy&#8217;s Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) stock increased 6.29%.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares upped 6.13% last week.</li>
</ol>
Photo by Sundry Photography via Shutterstock

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

<ul>
<li>Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)</li>
<li>Combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death</li>
<li>Launched in India in the same year as its launch in the U.S., making India the third country in the world to receive access to this New Biological Entity (NBE)</li>
</ul>

Reported Thursday, Dr. Reddy's Introduces Toripalimab In India, Immuno-Oncology Drug Approved For The Treatment Of Nasopharyngeal Carcinoma

Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL&#xAE; Tablets of Merck Sharp and Dohme LLC in the U.S. market. The product will be marketed by Dr. Reddy's.

Dr. Reddy's Laboratories, Senores Pharmaceuticals Launch Ivermectin Tablets USP, 3 mg In US Market

Dear Fellow Stockholder,
Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and to express my gratitude to our founder and Executive Chair, Dr. Howard Berman, whose bold vision has instilled the "innovation and get-it-done" culture in Coya's DNA. We have made tremendous strides in 2024, repeatedly executing on our promises. As I look to 2025, I am confident that our nimble and highly experienced team will continue to exceed expectations.
I have spent my entire 25-year career in the biotech space, and I believe that Coya has the most promise of any company that I have represented. I truly believe our novel science, strong clinical proof of concept data, pharmaceutical partnership validation, cash runway, and clear path to a commercial drug differentiates us. Prior to serving at Coya, I helped spearhead and lead pharmaceutical transactions worth billions of dollars that led to significant value creation. I believe the opportunities ahead of us in 2025 and beyond are what investors, stockholders, and patients should be most excited about. Our science and approach of regulating Tregs is now validated in multiple trials across multiple neurodegenerative diseases, we have a track record of executing value-creating non-dilutive deals, and our strong cash position allows us to be prudent in our decisions.
Year Ahead
We expect our activities in 2025 to be focused on the following indications:
ALS (Amyotrophic Lateral Sclerosis) Program: We have alignment with the FDA on the data required to initiate our potentially pivotal COYA 302 Phase 2 double-blind randomized study in patients with ALS. We are targeting the submission of the requested data package by 2Q 2025 and initiation of the clinical trial upon FDA clearance. The roadmap to topline results is now clear with reduced uncertainty. In late 2023, we partnered with Dr. Reddy's Laboratories, a multi-billion-dollar drug developer, to license COYA 302 in ALS in a deal that is worth up to $700 million. We still retain the rights to COYA 302 in ALS in Japan and South/Central America and Mexico, thus providing us direct upside and optionality in this indication alone.
FTD (Frontotemporal Dementia) Program: We expect to see topline results in 2H 2025 from the investigator-initiated, open-label study of Low Dose IL-2 (LD IL-2) + CTLA4-Ig in FTD. Study endpoints will measure safety, peripheral and central inflammation, FTD progression, and pharmacodynamic effects on Treg cell populations. The data are expected to guide our planned COYA 302 Phase 2 double-blind randomized study (which will be funded by the Alzheimer's Drug Discovery Foundation) and further optimize the design for success. The guidance from the FDA on the ALS IND reduces uncertainty on the planned IND filing for FTD in 2H of 2025. We have retained full commercial rights on this program thus far, providing us optionality to develop the program to BLA approval ourselves and capture the full potential upside or partner at a later stage once we obtain additional clinical data.
AD (Alzheimer's disease) Program: Complementing the promising data that was presented at CTAD in Madrid for LD IL-2 in mild to moderate AD, the investigators will disclose additional data in 1H 2025 that summarizes the changes in inflammation in the peripheral system (blood) and central nervous system (CSF and brain) and other molecular measurements for the two IL-2 dosing arms vs. placebo. These important data will help to further address the basic science associated with the promising clinical response observed in the lower dose IL-2 arm and its association with better Treg enhancement. We retain full rights to the AD indication for COYA 302 and are already in the process of exploring non-dilutive and strategic partnering opportunities. While the CTAD data was based on LD IL-2 alone and proved highly promising in and of itself, COYA 302, which is a proprietary combination of LD IL-2 and CTLA4-Ig, targets multiple pathways and is developed to more significantly and durably enhance Treg function, which we believe will be highly attractive to potential partners.
Strategic Partnerships
Dr. Reddy's Partnership: Our partnership with Dr. Reddy's Laboratories is approaching its one-year anniversary, and our collaboration could not be stronger. We have a reliable partner for ALS, and leveraging its resources and expertise has created value beyond the milestone payments. In 2025, we anticipate receiving $8.4 million upon initiation of the Phase 2 ALS clinical trial and will continue to evaluate opportunities to further deepen the relationship.
Other Strategic Possibilities: As I have described, my background is one of deal-making, and I intend to leverage my network and capabilities to maximize opportunities for Coya in 2025. We have only partnered COYA 302 in ALS, and the optionality to partner, co-develop, or license the asset in other indications exists. Any potential transaction will be evaluated based on maximizing stockholder value. The positive data from the investigator-initiated trial of LD IL-2 in patients with Alzheimer's disease increases our confidence in obtaining value-creating pharma partnerships that combine our proprietary LD IL-2, COYA 301, with other modalities. I can envision multiple opportunities with LD IL-2 serving as a backbone adjuvant with standard of care agents and other novel pathways.
Moreover, the opportunity for grant funding and financial support from foundations exists and will be vigorously pursued. We believe the data emerging on Tregs in autoimmune disease (such as lupus, rheumatoid arthritis, and scleroderma) and, in particular, treatment with LD IL-2 is compelling and may strengthen the role of COYA 302 and LD IL-2 combinations in this space. I intend to actively pursue partnerships in this arena that would further place us in a strong position to pursue value-creating deals.
Value-Creating Pipeline
Like many experts in the scientific community, we believe combination strategies are the future to address devastating neurodegenerative diseases. We believe targeting one mechanism or pathway is likely insufficient to achieve maximal effect - hence our approach with COYA 302. COYA 302 is a "Pipeline within a Product" and has strong potential in ALS, FTD, AD, Parkinson's disease, and other indications.
We are continuously building our intellectual property to further enhance the value of Coya. One recent development is the combination of COYA 301 and GLP-1 agonists. Data suggests that the mechanism of action appears additive and/or synergistic in ameliorating inflammation. This is yet another opportunity for value-creating strategic partnerships. We intend to publish more detailed data in 1Q 2025.
Conclusion
As you can see from our past performance, our entire management team is committed to the success of Coya. We expect to recognize a number of clinical, regulatory, and/or commercial milestones in 2025 that will help us advance the treatment of neurodegenerative diseases.
On behalf of the entire Coya team, please accept our sincere gratitude for both your support and belief in our science, our story, and our team. We look forward to presenting additional clinical data and updating you on our additional corporate developments as they unfold. Onwards and upwards!

COYA

Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive Funding To Advance Treg-Enhancing Biologics For Neurodegenerative And Autoimmune Diseases

Dr. Reddy&#8217;s Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) reported Tuesday a second-quarter 2025 net income of $160 million, down from $177 million a year ago.
Revenue increased from $821 million to $957 million — almost a 16.6% jump.
The strong revenue growth during the quarter was <a target="_blank" href="https://www.drreddys.com/cms/cms/sites/default/files/2024-11/Q2%20FY25%20Results%20.pdf" rel="noreferrer noopener">primarily</a> driven by growth in global generics revenues. The sequential growth was led by global generics revenues in Emerging Markets, India, Europe and Pharmaceutical Services and Active Ingredients (PSAI).
EBITDA for the quarter rose from $260 million to $272 million.
&#8220;We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell and related brands,&#8221; said co-chair GV Prasad.
Global generics revenues during the second quarter reached 71.6 billion rupees, showing a 17% year-over-year growth, driven by improved sales volumes and new product launches.
North American sales increased 17% (a sequential decline of 3%) to 37.3 billion rupees. YoY growth was largely due to increased sales volumes, partly offset by price erosion. The sequential decline was due to a decrease in sales volumes.
Gross Margin at 59.6% (GG: 63.1 %, PSAI: 30.0%), a YoY increase of 92 basis points (bps) and a QoQ decline of 81 bps. The YoY increase was due to an improvement in product mix and overhead leverage, partly offset by price erosion. On a sequential basis, the decline was primarily due to changes in the mix.
Price Action: Dr. Reddy&#8217;s Laboratories is up 4.81% at $15.51 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41745824/short-squeeze-globalfoundries-stock-soars-on-q3-earnings-beat-strong-q4-outlook" target="_blank" rel="noreferrer noopener">Short Squeeze &#8211; GlobalFoundries Stock Soars On Q3 Earnings Beat, Strong Q4 Outlook</a></li>
</ul>

Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%

General

Dr. Reddy's Laboratories shares are trading higher after the company reported a year-over-year increase in Q2 sales results.

Earnings

Dr Reddy's Laboratories Q2 2025 GAAP EPS $0.18 Compared To $0.21 YoY, Sales $957.00M Compared To $821M YoY

Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study – India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patients (100%) achieved clinical response, with 5/8 (62.5%) having achieved stringent complete response. With respect to safety, there were no high-grade events of Cytokine Release Syndrome (CRS) or neurotoxicity, in any of the patients.

Dr. Reddy's Subsidiary Aurigene Oncology, Announced Phase 1 Results For Ribrecabtagene Autoleucel From SWASTH Study; All 8 Patients Achieved Clinical Response

Dr. Reddy&#39;s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:<a href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as &quot;Dr. Reddy&#39;s&quot;)), today announced that it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other countries.
Lenacapavir is a United States Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally.
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca&reg; in the United States and Europe markets in the year 2022. It is a first-in-class HIV-1 capsid inhibitor.
Dr. Reddy&#39;s has been granted a non-exclusive voluntary licence to manufacture Lenacapavir and market it in 120 countries, for the current approved indication of HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV. Dr. Reddy&#39;s will be responsible for technology transfer at its manufacturing site, conducting bioequivalence/clinical studies, product registration and launch in the agreed markets. Additionally, the agreement grants licence to Dr. Reddy&#39;s to manufacture and commercialise lenacapavir for the indication of prevention of HIV (PrEP) in 120 countries, if approved.

Biotech

Global

GILD

Dr. Reddy's Signs Voluntary Licensing Agreement With Gilead Sciences To Manufacture And Commercialise Lenacapavir In India And Other Countries

Pending further discussions with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's"), Dr. Reddy's agreed to a partial deferral without penalty of a milestone payment by Citius Oncology, Inc. (the "Company"), which was triggered upon regulatory approval of LYMPHIRTM by the U.S. Food and Drug Administration and due on September 9, 2024, pursuant to the terms of the Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy's and Citius Pharmaceuticals, Inc. (the "Asset Purchase Agreement").

Contracts

CTOR

Dr. Reddy's Laboratories Agreed To Partially Defer A Milestone Payment From Citius Oncology, Inc., Due On September 9, 2024, Upon FDA Approval Of  LYMPHIR, Without Penalty, Pending Further Discussions, As Per Their 2021 Asset Purchase Agreement

Dr. Reddy's Issues Clarification Regarding Allegations Tied To Engagement With Agora Advisory; Confirms Engagement Of Dhaval Buch From October 2020 To April 2021, Prior To Madhabi Buch's SEBI Chairpersonship; Asserts Compliance With Laws And Denies Any Preferential Treatment By SEBI

Dr. Reddy's Receives FDA Form 483 With Three Observations Following Inspection At Srikakulam Facility

<ul>
<li>Malaria is a life-threatening public health issue, particularly in low- and middle-income countries. There is a need for an effective, affordable, and accessible preventive and/or treatment medication. This potential partnership is a step towards this cause</li>
<li>This potential partnership aims to bring together Kainomyx's expertise in novel drug discovery, Aurigene's capability to conduct integrated drug discovery and development, and Dr. Reddy's ability to commercialize products in low and middle-income countries, in addition to the US and Europe</li>
<li>It is a testament to the commitment of involved parties towards promoting global public health and Dr. Reddy's goal of reaching 1.5 billion patients by 2030</li>
</ul>
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:<a href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), and its CRDMO arm Aurigene Pharmaceutical Services Limited (Aurigene), today announced that they have signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc., a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, a novel mechanism of action, for the development and commercialization of affordable anti-malarial drug in the U.S., Europe, and in low and middle-income countries. The MoU remains subject to signing of a definitive agreement.

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, And Kainomyx Sign Non-Binding MoU For Joint Development Of Affordable Anti-Malarial Drug

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) with a Overweight and raises the price target from $81 to $87.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:<a href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the launch of its proposed biosimilar Rituximab candidate DRL_RI (ITUXREDI&#xAE;) in European markets.
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance and drug product manufacturing facility located in Hyderabad, India. As part of the established approval process, the CHMP positive opinion will now be reviewed by the European Commission (EC), following which a decision will be made on the grant of marketing authorisation in the European Union (EU) member countries, and the European Economic Area (EEA) member states of Norway, Iceland, and Liechtenstein. A Marketing Authorisation Application (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA) will be made separately in keeping with the reliance route under the International Recognition Procedure (IRP).

Dr. Reddy's Receives Positive CHMP Opinion From EMA For Its Proposed Rituximab Biosimilar Candidate DRL_RI

Dr Reddy's Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) reported quarterly earnings of ₹83.46 per share which beat the analyst consensus estimate of $76.83 by 8.63 percent. This is a 0.9 percent decrease over earnings of ₹84.22 per share from the same period last year. The company reported quarterly sales of ₹76.727 billion which beat the analyst consensus estimate of ₹72.830 billion by 5.35 percent. This is a 13.87 percent increase over sales of ₹67.384 billion the same period last year.

Earnings Beats

Dr Reddy's Laboratories Q1 2025 GAAP EPS ₹83.46 Beats ₹76.83 Estimate, Sales ₹76.727B Beat ₹72.830B Estimate

Dr. Reddy's Signs Non-Exclusive Patent Licensing Agreement With Takeda To Commercialize Vonoprazan In India

Dr. Reddy&#39;s Laboratories&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rdy#NYSE">RDY</a>) has announced a definitive agreement with Haleon plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hln#NYSE">HLN</a>) to acquire its global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy&nbsp;category, excluding the United States.
The impending acquisition will add Nicotinell, Haleon&#39;s leading NRT brand with a presence in more than 30 countries across the EU, Asia (including Japan) and Latin America, to RDY&#39;s portfolio of global consumer healthcare over-the-counter (OTC) drugs. It also encompasses local market-leading brands, such as Nicabate in Australia, Thrive in Canada and Habitrol in New Zealand and Canada. The acquisition will cover all product formats, including lozenge, patch, gum and pipeline products, in all applicable global markets outside the United States.
The strategic move is set to further strengthen Dr. Reddy&#39;s OTC business. Please note that Haleon&#39;s Nicotinell is the world&#39;s second-largest brand in the NRT category, excluding the United States. It holds either the first or second position in 14 out of the top 17 global markets, with its lozenge/mini lozenge format being the top choice globally. Additionally, Nicotinell is among the top 15 OTC brands in Europe (excluding Russia and Italy) and ranks 32nd among all OTC brands globally (excluding the United States). In 2023, Nicotinell generated approximately GBP 217 million in revenues.
The proposed acquisition of Nicotinell and its related portfolio will provide a strong presence in the EU and other global markets, complementing and expanding Dr. Reddy&#39;s existing global footprint and capabilities.
Year to date, shares of RDY have gained 3.5% compared with the industry&#39;s 6.7% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/31/69712.jpg?v=1289112071" style="height:350px; width:600px" /> 
Image Source: Zacks Investment Research
In consideration of the transaction, Dr. Reddy&#39;s is liable to make an upfront cash payment of GBP 458 million and performance-based contingent payments of up to GBP 42 million, payable in 2025 and 2026, to Haleon. This brings the total deal value to GBP 500 million.&nbsp;
Subject to the fulfillment of certain customary conditions, including regulatory approvals, the transaction is expected to close early in the fourth quarter of 2024. Consequently, Dr. Reddy&#39;s will acquire Haleon&#39;s NRT business in all countries outside of the United States. However, operations will transition to Dr. Reddy&#39;s in a phased approach to ensure successful integration of the business.
Tobacco use causes eight million deaths annually from health issues like cardiovascular diseases, lung disorders, cancers and diabetes. The World Health Organization (WHO) reports that 60% of the 1.3 billion tobacco users globally want to quit, but only 30% have access to the necessary tools. Although safe and effective medical treatments are available, they are not always accessible or sufficiently provided.
Please note that NRT is recommended by the WHO&#39;s Model List of Essential Medicines for treating nicotine use disorders. NRT also played a crucial role in the WHO&#39;s Access Initiative for Quitting Tobacco, which was launched in 2020 and aimed at helping tobacco users quit to reduce the risk of severe outcomes from COVID-19 infection.
Dr. Reddy&#39;s focuses on generics, branded generics, Active Pharmaceutical Ingredients, OTC products and biosimilars while investing in growth areas like novel molecules (NCEs, NBEs, CAR-T), digital therapeutics and consumer healthcare. In the United States, it has acquired brands like Habitrol, Doan&#39;s, Premama and the MenoLabs portfolio. In India, its portfolio includes hydration, cough-cold-allergy and skincare products, with a joint venture with Nestl&eacute; India for nutritional health solutions.
Dr. Reddy&#39;s also has a strong OTC presence in emerging markets. It recently entered into the U.K. market with Histallay. The company is enhancing its brand-building, marketing, digital and e-commerce capabilities.
<h3>Zacks Rank and Stocks to Consider</h3>
Dr. Reddy&#39;s currently carries a Zacks Rank #3 (Hold). &nbsp;
Some better-ranked stocks from the drug/biotech industry are ALX Oncology Holdings&nbsp;and Annovis Bio, each carrying a Zacks Rank #2 (Buy) at present.
In the past 30 days, the Zacks Consensus Estimate for ALX Oncology&#39;s 2024 loss per share has remained constant at $2.89. During the same period, the consensus estimate for 2025 loss per share has remained constant at $2.73. Year to date, shares of ALXO have plunged 60.5%.
ALX Oncology beat estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 8.83%.
In the past 30 days, the Zacks Consensus Estimate for Annovis&#39; 2024 loss per share has remained constant at $2.46. During the same period, the consensus estimate for 2025 loss per share has remained constant at $1.95. Year to date, shares of ANVS have plunged 69.4%.
ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.
<a href="https://www.zacks.com/stock/news/2294456/dr-reddy-s-rdy-to-acquire-haleon-s-nicotine-addiction-drug?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2294456">To read this article on Zacks.com click here.</a>

Health Care

Markets

Dr. Reddy's to Acquire Haleon's Nicotine Addiction Drug

WIIM

Dr. Reddy's Laboratories shares are trading higher. The company on Wednesday announced it signed a definitive agreement with Haleon for purchase of shares of Northstar Switzerland SARL to acquire its global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy category outside of the United States.

On Wednesday, Haleon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) agreed to sell its <a href="https://www.benzinga.com/topic/tobacco">nicotine replacement therapy</a> business outside of the U.S. to Dr. Reddy's Laboratories SA, a wholly owned subsidiary of Dr. Reddy's Laboratories Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) for 500 million pounds (around $632 million).
The nicotine replacement therapy (NRT) portfolio consists of brands such as Nicotinell, Nicabate, Habitrol, and Thrive, which are available in gum, lozenge, and patch forms across over 30 markets.&nbsp;
The 500 million pound <a href="https://www.haleon.com/news/press-releases/brand/2024/haleon-to-divest-nicotine-replacement-therapy-business-outside-o">consideration</a> is structured as an upfront cash payment of 458 million pounds, with a further up to 42 million pounds deferred performance-based consideration payable during 2025 and H1 2026.
The transaction is expected to be completed in early Q4 2024.&nbsp;
This divestment will allow Haleon to exit the nicotine replacement therapy category outside the U.S. and reduce complexity across the business, allowing it to focus more on strategic growth areas. 
The nicotine replacement therapy business had a net revenue of 217 million pounds and a net profit of 110 million pounds for the financial year ended Dec. 31, 2023.
Assuming the transaction is completed in early Q4 2024, this divestment is expected to dilute fiscal year 2024 net revenue and adjusted operating profit by c. 0.5% and c. 1%, respectively.
All other fiscal year 2024 guidance, as shared in the first quarter trading statement is unchanged.&nbsp;
Brian McNamara, chief executive officer of Haleon, commented: "The divestment of Haleon's NRT business outside of the U.S. is a further example of Haleon being proactive in managing its portfolio and is consistent with our strategy as we implement change to become more agile and competitive. Whilst this business has great brands, these are not core for us, but I&#8217;m sure they will continue to flourish given the focus and capability of Dr Reddy&#8217;s." 
Price Action: RDY stock is down 0.04% at $71.78, and HLN shares are down 0.64% at $8.52 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/06/39502281/judge-tosses-the-card-visa-mastercard-swipe-fee-settlement-reportedly-rejected">Judge Tosses The Card: Visa-Mastercard Swipe Fee Settlement Reportedly Rejected</a></li>
</ul>
Photo: Poetra.RH/Shutterstock.com

Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M

Dr. Reddy's (RDY) Laboratories and Senores Pharmaceuticals announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therape...

Dr. Reddy's and Senores launch Ivermectin tablets USP, 3  mg in U.S.

Dr Reddy's Laboratories (RDY) has released an update. Dr. Reddy's Laboratories has received fines from Germany's Federal Administration Office for ...

Dr. Reddy's Fined in Germany for Registration Lapse

Dr Reddy's Laboratories (RDY) has released an update. Dr. Reddy's Laboratories has launched Toripalimab in India, marking it as the first immuno-on...

Dr. Reddy's Launches Innovative Cancer Drug in India

Dr Reddy's Laboratories (RDY) has released an update. Dr. Reddy's Laboratories has announced the allotment of 26,150 equity shares to employees who...

Dr. Reddy's Boosts Workforce with Equity Allotment

Dr Reddy's Laboratories (RDY) has released an update. Dr. Reddy's Laboratories is set to engage with investors through a group meeting organized by...

Dr. Reddy's Laboratories to Host Investor Meeting

Dr Reddy's Laboratories (RDY) has released an update. Dr. Reddy's Laboratories LLC, a subsidiary in Ukraine, has been fined EUR 280 by the State Ta...

Dr. Reddy's Subsidiary Faces Minor Penalty in Ukraine

Nomura downgraded Dr. Reddy's (RDY) to Neutral from Buy with a INR 1,500 price target The firm thinks the Street is concerned about higher contribu...

Dr. Reddy's downgraded to Neutral from Buy at Nomura

Impax Global Opportunities Fund Q3 2024 Commentary

Impax Global Social Leaders Fund Q3 2024 Commentary

Dr Reddy's Laboratories ( ($RDY) ) has provided an update. Dr. Reddy's Laboratories has approved the allotment of 13,080 equity shares to employees...

Dr. Reddy's Laboratories Allocates Equity Shares to Employees

AAGIY

AAIGF

AMAT

ASML

ASMLF

CDNS

CTAS

DUOL

EBAY

HLNCF

INTC

INTU

ISRG

KRYAF

KRYAY

MBLY

MELI

NONOF

WOLTF

WTKWY

Press Releases

Dr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

Market Alert: Dr. Reddy's Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression

Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Dr. Reddy's Q2 & H1FY25 Financial Results

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Dr Reddy's Laboratories

Dr Reddy's Laboratories (RDY) 옵션

Dr Reddy's Laboratories (NYSE:RDY) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌